ERBB2 and breast carcinoma: Although the methods for detecting ESR1 or HER2 in breast cancer biopsies by immunohistochemistry are well established [29], AR immunohistochemistry performed on tumor biopsies is not routine or standardized leading to a wide variation in the reported number of AR-positive breast cancer cases [27, 28].